{"filing":{"accession_number":"0001178913-26-004628","cik":"0002022416","ticker":"SLXNW","company_name":"Silexion Therapeutics Corp","form":"8-K","filing_date":"2026-09-28","report_date":"2026-09-28","primary_document":"zk2636165.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2022416/000117891326004628/zk2636165.htm"},"events":[{"id":35345,"run_id":32551,"accession_number":"0001178913-26-004628","anchor_item_number":"7.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.72,"summary":"This disclosure reports positive preclinical findings for SIL204 demonstrating a key cellular uptake mechanism via native lipoprotein pathways. While framed as a Regulation FD disclosure (Item 7.01), the substance is a material operational/scientific milestone supporting the company's Phase 2/3 clinical development program. The findings validate a core mechanism of action and provide mechanistic support for systemic administration strategy, which would materially affect investor assessment of the lead candidate's therapeutic potential and clinical viability. This is operational progress rather than a specific event type (not earnings, M\u0026A, litigation, etc.), making operational_other the most appropriate classification.","company_name":"Silexion Therapeutics Corp","ticker":"SLXNW","filing_date":"2026-09-28","form":"8-K","submitted_at":null,"items":[{"id":39367,"accession_number":"0001178913-26-004628","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.72,"reasoning":"This disclosure reports positive preclinical findings for SIL204 demonstrating a key cellular uptake mechanism via native lipoprotein pathways. While framed as a Regulation FD disclosure (Item 7.01), the substance is a material operational/scientific milestone supporting the company's Phase 2/3 clinical development program. The findings validate a core mechanism of action and provide mechanistic support for systemic administration strategy, which would materially affect investor assessment of the lead candidate's therapeutic potential and clinical viability. This is operational progress rather than a specific event type (not earnings, M\u0026A, litigation, etc.), making operational_other the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-28T12:47:56.630918+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":39367,"accession_number":"0001178913-26-004628","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.72,"reasoning":"This disclosure reports positive preclinical findings for SIL204 demonstrating a key cellular uptake mechanism via native lipoprotein pathways. While framed as a Regulation FD disclosure (Item 7.01), the substance is a material operational/scientific milestone supporting the company's Phase 2/3 clinical development program. The findings validate a core mechanism of action and provide mechanistic support for systemic administration strategy, which would materially affect investor assessment of the lead candidate's therapeutic potential and clinical viability. This is operational progress rather than a specific event type (not earnings, M\u0026A, litigation, etc.), making operational_other the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-28T12:47:56.630918+00:00","company_name":"Silexion Therapeutics Corp","ticker":"SLXNW","filing_date":"2026-09-28"}]}